Inovio’s shares plunge after FDA holds-off its COVID-19 vaccine Phase II/III trial
Inovio’s COVID-19 vaccine, INO-4800, Phase II/III clinical trials’ have been put under partial hold after the USFDA raised questions. The firm mentioned the reason behind the halt of the trials is not due to adverse events in the Phase I study and is not impacted in any way.
The clinical hold, besides INO-4800, also raises questions about Inovio’s Cellectra 2000 delivery device. The company is trying to address all the concerns the regulatory authority has by October.
As a part of the Operation Warp Speed that aims to make available the vaccine by January 2021...
